Mind-altering substances are (still) falling short in clinical trials

Placebo and "knowcebo" effects are a problem. But they can also help people feel better. This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin--which is found in magic mushrooms--are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over the last decade, we've seen scientific interest in these drugs explode. But most clinical trials of psychedelics have been small and plagued by challenges.